Global Pharmaceutical Continuous Manufacturing Market, By Product Type (Integrated Systems, Semi-Continuous Systems, and Controls, Continuous Granulators, Continuous Coaters, Continuous Blenders, Continuous Dryers, Other Semi- Continuous Systems), Application Type (Active Pharmaceutical Ingredient, Dry Powders, and Biologics, End Product Manufacturing, and Solid Dosage), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), End User (Research and Development Departments and Full-Scale Manufacturing Companies, Contact Manufacturing Organizations (CMOs), Pharmaceuticals Companies, Research Institutes, and Contact Research Organizations (CROs) – Industry Trends and Forecast to 2031.
Pharmaceutical Continuous Manufacturing Market Analysis and Size
The global pharmaceutical continuous manufacturing market is propelled by cost-effectiveness, efficiency, and regulatory support. Continuous manufacturing ensures streamlined production processes, consistent product quality, and faster time-to-market. It finds applications in tablet production, granulation, coating, and integrated process control, offering supply chain integration and enhanced traceability for pharmaceutical companies worldwide.
Data Bridge Market Research analyses that the global pharmaceutical continuous manufacturing market was growing at a value of USD 2.86 billion in 2023 and is expected to reach a value of USD 5.35 billion in 2031 and register a CAGR of 8.16% from 2024 to 2031. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, import/export analysis, pricing analysis, production consumption analysis, patent analysis and consumer behavior.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Integrated Systems, Semi-Continuous Systems, and Controls, Continuous Granulators, Continuous Coaters, Continuous Blenders, Continuous Dryers, Other Semi- Continuous), Application Type (Active Pharmaceutical Ingredient, Dry Powders, and Biologics, End Product Manufacturing, and Solid Dosage), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), End User (Research and Development Departments and Full-Scale Manufacturing Companies, Contact Manufacturing Organizations (CMOs), Pharmaceuticals Companies, Research Institutes, and Contact Research Organizations (CROs))
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America
|
|
Market Players Covered
|
GEA Group Aktiengesellschaft (Germany), Thermo Fisher Scientific Inc. (U.S.), Hosokawa Micron Group (Japan), Robert Bosch GmbH 9Germeany), Glatt GmbH (India), Siemens (Germany), Coperion GmbH (Germany), Aurobindo Pharma (India), L.B. Bohle Maschinen und Verfahren GmbH (Germany), Dr. Reddy’s Laboratories Ltd. (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), and Sanofi (France) among others
|
|
Market Opportunities
|
|
Market Definition
Pharmaceutical continuous manufacturing is a production method where pharmaceuticals are manufactured continuously without interruption. It involves the streamlined and integrated processing of raw materials into finished products, such as tablets, capsules, and other dosage forms.
Global Pharmaceutical Continuous Manufacturing Market Dynamics
Drivers
- Continuous Manufacturing in Pharmaceuticals Facilitates Cost Savings
Continuous manufacturing in pharmaceuticals facilitates cost savings by optimizing operations, cutting labor requirements, reducing energy consumption, and minimizing material waste. Its uninterrupted processes enhance efficiency and resource utilization, leading to improved profitability and competitiveness for pharmaceutical companies. These advantages make it a strategic choice for companies aiming to enhance their bottom line and market position.
- Continuous Manufacturing Enhances Resource Efficiency
Continuous manufacturing enhances resource efficiency by minimizing downtime between production cycles, optimizing equipment utilization, and reducing the need for manual intervention. With continuous processes, pharmaceutical companies can streamline their operations, reduce waste, and utilize resources more effectively. By integrating automation and advanced control systems, continuous manufacturing ensures precise monitoring and adjustment of parameters, maximizing resource utilization while maintaining product quality and consistency, ultimately improving overall operational efficiency.
Opportunities
- Regulatory Agencies Encouraging the Adoption of Continuous Manufacturing
Regulatory agencies, such as the FDA and EMA, are encouraging the adoption of continuous manufacturing to enhance drug quality, ensure consistent product standards, and expedite drug development and approval processes. Their endorsement stems from the method's capacity to enhance process control and product quality monitoring, thus minimizing variations. By encouraging its adoption, regulatory bodies aim to modernize manufacturing practices, boost efficiency, and maintain stringent quality standards across the pharmaceutical industry, thereby fostering market growth and widespread adoption.
- Increased Efficiency and Productivity by Continuous Manufacturing Processes
Continuous manufacturing processes transform efficiency in pharmaceutical production by drastically cutting production cycle times, minimizing manual interventions, and boosting overall productivity in contrast to traditional batch manufacturing. By streamlining operations and eliminating batch-related downtimes, continuous processes ensure seamless production flows and rapid product turnaround. Automation and real-time monitoring further enhance efficiency, enabling immediate adjustments and quality assurance measures. Consequently, pharmaceutical companies can meet market demands swiftly, reduce costs, and maintain high-quality standards, enhancing competitiveness in the industry.
Restraints/Challenges
- Risk of Technology Failure Impact Production Efficiency
Continuous manufacturing systems are reliant on automation, control systems, and software platforms, which may be prone to technical glitches, software failures, or equipment malfunctions. The risk of technology failure and process disruptions can impact production efficiency, product quality, and regulatory compliance, posing risks to patient safety and business continuity.
- Initial Investment Costs
Implementing continuous manufacturing requires significant upfront investment in equipment, technology upgrades, staff training, and process validation. The high initial costs associated with transitioning from traditional batch manufacturing to continuous processes may deter some pharmaceutical companies from adopting these technologies.
This global pharmaceutical continuous manufacturing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global pharmaceutical continuous manufacturing market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In March 2022, USP India extended its presence in Hyderabad, announcing plans for a new continuous manufacturing facility with an added capital injection of USD 20 million. This expansion underscores USP's commitment to enhancing its operations and services in India's pharmaceutical sector
- In March 2022, Phlow Corp, a U.S. based public benefit company specializing in essential medicines, partnered with Virginia Commonwealth University (VCU) Medicines for All Institute and AMPAC Fine Chemicals. The collaboration aims to offer contract research and development services for small molecule pharmaceutical products, focusing on continuous manufacturing, thereby bolstering the pharmaceutical industry's capabilities and innovation
Global Pharmaceutical Continuous Manufacturing Market Scope
The global pharmaceutical continuous manufacturing market is segmented into four notable segments based on product type, application type, distribution channel, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Integrated Systems
- Semi-Continuous Systems
- Controls
- Continuous Granulators
- Continuous Coaters
- Continuous Blenders
- Continuous Dryers
- Other semi-continuous Systems
Application Type
- Active Pharmaceutical Ingredient
- Dry Powders
- Biologics
- End Product Manufacturing
- Solid Dosage
Distribution Channel
- Retail Pharmacy
- Online Pharmacy
- Hospital Pharmacy
End User
- Research and Development Departments
- Full-Scale Manufacturing Companies
- Contact Manufacturing Organizations (CMOs)
- Pharmaceuticals Companies
- Research Institutes
- Contact Research Organizations (CROs)
Global Pharmaceutical Continuous Manufacturing Market Regional Analysis/Insights
The global pharmaceutical continuous manufacturing market is analysed and market size insights and trends are provided by based on product type, application type, distribution channel, and end user as referenced above.
The countries covered in the global pharmaceutical continuous manufacturing market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.
Europe dominates the global pharmaceutical continuous manufacturing market due to its stringent regulatory environment, fostering innovation and adoption of advanced manufacturing techniques. The region boasts a well-established pharmaceutical industry, extensive research infrastructure, and strong support for technological development.
Asia-Pacific is the fastest-growing region in the global pharmaceutical continuous manufacturing market due to increasing investments in pharmaceutical manufacturing infrastructure, rising adoption of advanced technologies, expanding pharmaceutical markets, growing demand for affordable healthcare solutions, and supportive government initiatives promoting innovation and development in the region.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Pharmaceutical Continuous Manufacturing Market Share Analysis
The global pharmaceutical continuous manufacturing market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global pharmaceutical continuous manufacturing market.
Some of the major players operating in the global pharmaceutical continuous manufacturing market are:
- GEA Group Aktiengesellschaft (Germany)
- Thermo Fisher Scientific Inc. (U.S.)
- Hosokawa Micron B.V. (Japan)
- Robert Bosch GmbH 9Germeany)
- Glatt GmbH (India)
- Siemens (Germany)
- Coperion GmbH (Germany)
- Aurobindo Pharma (India)
- L.B. Bohle Maschinen und Verfahren GmbH (Germany)
- Dr. Reddy’s Laboratories Ltd. (India)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Sanofi (France)
SKU-